A2058Homo sapiens (Human)Cancer cell line
Also known as: A-2058, A 2058, A2658
Quick Overview
Human melanoma cell line with known BRAF and NRAS mutations, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1059 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lymph node[UBERON:UBERON_0000029] |
Donor Information
| Age | 43 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Amelanotic melanoma |
|---|---|
| Lineage | Skin |
| Subtype | Melanoma |
| OncoTree Code | MEL |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000788_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP63 | p.Arg379Cys (c.1135C>T) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | TP53 | p.Val274Phe (c.820G>T) | Homozygous | - | PubMed=30737244, PubMed=29846633 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
| MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Metastatic melanoma cell lines do not secrete IL-1beta but promote IL-1beta production from macrophages.
Cheng P., Dummer R., Kerl K., Contassot E., French L.E.
J. Dermatol. Sci. 74:167-169(2014).
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Rosen N., Solit D.B.
Cancer Res. 74:2340-2350(2014).
Functional profiling of live melanoma samples using a novel automated platform.
Schuchter L.M., Clark D.P.
PLoS ONE 7:E52760-E52760(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.
Mol. Cancer Ther. 11:888-897(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Friedman H.S., Nevins J.R., Ali-Osman F., Tyler D.S.
Clin. Cancer Res. 15:502-510(2009).
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Johansson P., Pavey S., Hayward N.K.
Pigment Cell Res. 20:216-221(2007).
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Sharpless N.E.
Cancer Res. 67:1502-1512(2007).
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Oncogene 23:8796-8804(2004).
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Meltzer P.S., Ringner M., Hayward N.K.
Oncogene 23:4060-4067(2004).
Characterization of human melanoma cell lines according to their migratory properties in vitro.
Quinones L.G., Garcia-Castro I.
In Vitro Cell. Dev. Biol. Anim. 40:35-42(2004).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p.
Adam Z., Adany R., Ladanyi A., Timar J., Balazs M.
Clin. Exp. Metastasis 18:295-302(2000).
Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells.
Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.
Int. J. Cancer 75:590-595(1998).
CDKN2A/p16 is inactivated in most melanoma cell lines.";
Gabrielli B.G., Parsons P.G., Hayward N.K.
Cancer Res. 57:4868-4875(1997).
Expression of the co-stimulatory molecule CD40 on melanoma cells.";
Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.
Int. J. Cancer 68:795-801(1996).
Expression of the co-stimulatory molecule B7 on melanoma cells.";
Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.
Int. J. Cancer 58:527-532(1994).
Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.
Todaro G.J., Fryling C.M., De Larco J.E.
Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980).
Selection and characterization of human melanoma lines with different liver-colonizing capacity.
Ladanyi A., Timar J., Paku S., Molnar G., Lapis K.
Int. J. Cancer 46:456-461(1990).
Nerve growth factor receptors on human melanoma cells in culture.";
Fabricant R.N., De Larco J.E., Todaro G.J.
Proc. Natl. Acad. Sci. U.S.A. 74:565-569(1977).
Modal karyotype of continuous cell line A2058 (human metastatic melanoma) and its evolution in culture.
Dzhambazov B., Asparuhova D., Koleva L., Popov N.
Caryologia 54:313-317(2001).